MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.355
-0.035 (-2.52%)
Jun 25, 2026, 4:00 PM EDT - Market closed
MAIA Biotechnology Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum, elected two directors for three-year terms, and ratified the appointment of independent auditors. Shareholders participated virtually, with questions addressed during and after the meeting.
Fiscal Year 2025
-
THIO, a novel telomere-targeting immunotherapy, is advancing through pivotal trials for hard-to-treat cancers, showing high efficacy and safety. Multiple partnerships, orphan drug designations, and a strong patent portfolio support its commercial potential, with key data and regulatory milestones expected through 2026.